• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Justin Iacobucci

Article

Justin Iacobucci, Associate Publisher.

T: (978) 567-0601
F: (617) 969-2118
jiacobucci@advanstar.com

Justin joined Pharmaceutical Executive in November 2006. Justin has extensive experience in all aspects of media business with a heightened focus on strategizing and building integrated electronic media programs. Justin is based in Massachusetts.

Area covered: New England, New Jersey, Mid-Atlantic, Southeast

Related Videos
Related Content
FDA Approves Amneal’s Naloxone Hydrochloride Nasal Spray as an OTC Treatment for Opioid Overdose

FDA Approves Amneal’s Naloxone Hydrochloride Nasal Spray as an OTC Treatment for Opioid Overdose

April 24th 2024
Article

Company aims to provide affordable emergency treatment from overdoses of heroin, fentanyl, and prescription opioids.

Fierce Females in the Life Science Space

Fierce Females in the Life Science Space

March 29th 2024
Podcast

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

Image credit: peterschreiber.media | stock.adobe.com

FDA Grants Accelerated Approval to Day One’s Ojemda for Relapsed or Refractory Pediatric Low-Grade Glioma

April 24th 2024
Article

Ojemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.

Gen-Z Influence on Pharma M&A

Gen-Z Influence on Pharma M&A

March 14th 2024
Podcast

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Pharma Pulse 4/24/24: 5 Things You Should Know About Women's Health, Microsoft Makes Push Into Smaller AI Systems & more

Pharma Pulse 4/24/24: 5 Things You Should Know About Women's Health, Microsoft Makes Push Into Smaller AI Systems & more

April 24th 2024
Article

The latest news for pharma industry insiders.

Image credit: Yuriy | stock.adobe.com

FDA Approves Novartis' Lutathera for Pediatric Patients with Gastroenteropancreatic Neuroendocrine Tumors

April 23rd 2024
Article

Lutathera is the first FDA-approved treatment for younger patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.